# Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

> **NCT03178851** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 155 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **DRUG:** Cobimetinib
- **BIOLOGICAL:** Atezolizumab
- **BIOLOGICAL:** Atezolizumab

## Key facts

- **NCT ID:** NCT03178851
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-20
- **Primary completion:** 2019-05-29
- **Final completion:** 2020-09-21
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178851, "Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03178851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*